Investigational drug · Phase 3
MRG003
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Recurrent or Metastatic Nasopharyngeal Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Advanced Solid Tumors.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
53
Any phase or sponsor naming "MRG003"
First trial start
2022
Jun 30, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MRG003", any sponsor or status.
- Phase 244
Conditions studied
As listed on its trial records.
- Recurrent or Metastatic Nasopharyngeal Carcinoma
- Squamous Cell Carcinoma of the Head and Neck
- Advanced Solid Tumors
Approved drugs for the same conditions: Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "MRG003" as an intervention, largest first.
- A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal CarcinomaPivotal-lookingRecruiting
Lepu Biopharma Co., Ltd.Industry
NCT06976190 · 446 participants (planned) · Start May 6, 2025 · Primary completion May 2029
Drug: MRG003 + Pucotenlimab; Gemcitabine, Docetaxel, or Capecitabine · For: Recurrent or Metastatic Nasopharyngeal Carcinoma
Sites: Guangzhou, China
- Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell CarcinomaPivotal-lookingRecruiting
Ming-Yuan ChenAcademic, hospital or other
NCT07524452 · 430 participants (planned) · Start Feb 6, 2026 · Primary completion Feb 28, 2031
Drug: Neoadjuvant and Adjuvant Becotatug Vedotin; Neoadjuvant and Adjuvant Immunotherapy and 1 more · For: Locally Advanced Head and Neck Squamous Cell Carcinoma
Sites: Zhuhai, China
- Dynamic Plasma EBV DNA-Guided Risk-Adapted Treatment With Becotatug Vedotin (MRG003) Plus PD-1 Blockade in Locoregionally Advanced Nasopharyngeal CarcinomaNot yet recruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT07524413 · 298 participants (planned) · Start Dec 2026 · Primary completion Dec 2031
Drug: Becotatug Vedotin; Pucotenlimab and 2 more · For: Nasopharyngeal Cancinoma (NPC); Nasopharyngeal Cancer
- A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal CarcinomaPivotal-lookingActive, not recruiting
Lepu Biopharma Co., Ltd.Industry
NCT05126719 · 238 participants (planned) · Start Apr 6, 2023 · Primary completion Dec 30, 2024
Drug: MRG003; Capecitabine tablets and 1 more · For: Recurrent or Metastatic Nasopharyngeal Carcinoma
Sites: Beijing, China; Chongqing, China; Fuzhou, China · 23 sites in all
- Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT07825753 · 225 participants (planned) · Start Sep 10, 2026 · Primary completion Sep 1, 2027
Drug: Trastuzumab emtansine (T-DM1); Trastuzumab deruxtecan (T-DXd) and 6 more · For: Advanced or Metastatic Pancreatic Adenocarcinoma; Advanced or Metastatic Breast Cancer (BC)
Sites: Shanghai, China
- Efficacy and Safety of SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Positive Metastatic Tumor Patients With OligometastasesPivotal-lookingRecruiting
Ming-Yuan ChenAcademic, hospital or other
NCT07481799 · 200 participants (planned) · Start Feb 6, 2026 · Primary completion Feb 28, 2029
Drug: Becotatug Vedotin; Systemic Therapy/Standard of Care · For: Oligo-metastatic Cancer
Sites: Zhuhai, China · 2 sites in all
- A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHNPivotal-lookingRecruiting
Lepu Biopharma Co., Ltd.Industry
NCT05751512 · 180 participants (planned) · Start Apr 4, 2023 · Primary completion Dec 2027
Drug: MRG003; Cetuximab injection and 1 more · For: Squamous Cell Carcinoma of the Head and Neck
Sites: Shanghai, China
- Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and NeckPivotal-lookingRecruiting
Groupe Oncologie Radiotherapie Tete et CouAcademic, hospital or other
NCT06959108 · 106 participants (planned) · Start Oct 13, 2025 · Primary completion Jun 2029
Drug: Pucotenlimab; MRG003 · For: Locally Advanced Head and Neck Squamous Cell Carcinoma
Sites: Villejuif, France
Ji DongmeiAcademic, hospital or other
NCT07464366 · 90 participants (planned) · Start Mar 19, 2026 · Primary completion May 30, 2028
Drug: MRG 003; Pucotenlimab · For: Salivary Gland Carcinomas
Sites: Shanghai, China
Lepu Biopharma Co., Ltd.Industry
NCT04838548 · 87 participants · Start Apr 16, 2021 · Primary completion Mar 27, 2023
Drug: MRG003 · For: Carcinoma, Non-Small-Cell Lung
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- An evaluation of becotatug vedotin for the treatment of recurrent or metastatic nasopharyngeal cancer.
Wang X, Han F · Expert Opin Biol Ther 2026
- Comprehensive analysis of antibody-drug conjugate (ADC) targets in adenoid cystic carcinoma: examining antigen expression in relation to clinicopathological features, prognosis, and initial therapeutic outcomes.
Wang Y, Dou S, Jiang W, et al. · Transl Oncol 2026
- Is EGFR back? ADCs revive targeted therapy in nasopharyngeal carcinoma.
Kanemura H, Hayashi H · Med 2026
- Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial.
Han F, Lv X, Zhou YJ, et al. · Med 2026
- A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies.
Jiménez-Labaig P, Rullan A, Hernando-Calvo A, et al. · Cancer Treat Rev 2024
- Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial.
Qiu MZ, Zhang Y, Guo Y, et al. · JAMA Oncol 2022
Also in development for Recurrent or Metastatic Nasopharyngeal Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- PucotenlimabHX008Phase 36 trials
Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.